Page 72 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 7 of 7 Opinion Paper

26. Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected 46. Llibre JM, Hung C-C, Brinson C, et al. Phase III SWORD 1&2: Switch to DTG+RPV
pregnant women. J Acquir Immune Defic Syndr. 2016;72(3):289–296. maintains virologic suppression through 48 wks. Conference on Retroviruses and
27. Schalkwijk S, Colbers A, Konopnicki D, et al. Lowered rilpivirine exposure during Opportunistic Infections; 13–16 February 2017; Seattle, WA; 2017.
third trimester of pregnancy in HIV-1-positive women. Clin Infect Dis. 47. Capetti AF, Sterrantino G, Cossu MV, et al. Switch to dolutegravir plus rilpivirine
2017;65(8):1335–1341. https://doi.org/10.1093/cid/cix534 dual therapy in cART-experienced subjects: An observational cohort. PLoS One.
28. APRS Committee. Antiretroviral Pregnancy Registry international interim report 2016;11(10):e0164753. https://doi.org/10.1371/journal.pone.0164753
for 1 January 1989 through 31 January 2017. Wilmington, NC: Registry 48. Díaz A, Casado J, Dronda F, et al. Dolutegravir plus rilpivirine in suppressed heavily
Coordinating Center; 2017. pretreated HIV-infected patients. 21st International AIDS Conference; Durban,
29. Bangalee V, Suleman F. Cost-savings accruable to removing value added tax from South Africa; 2016.
antiretrovirals in the South African private health sector. Health SA Gesondheid. 49. Revuelta-Herrero JL, Chamorro-De-Vega E, Rodriguez-Gonzalez CG, Alonso R,
2017;22(1):150–156. https://doi.org/10.1016/j.hsag.2016.11.003 Herranz-Alonso A, Sanjurjo-Saez M. Effectiveness, safety, and costs of a treatment
switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced
30. World Health Organization. WHO consolidated guidelines on the use of antiretroviral HIV patients. Ann Pharmacother. 2018;52(1):11–18. https://doi.org/10600280
drugs for treating and preventing HIV infection. Geneva: WHO; 2016. 17728294
31. Sinxadi PZ, Leger PD, McIlleron HM, et al. Pharmacogenetics of plasma efavirenz 50. McKee S. ViiV/Janssen’s two-drug HIV regimen filed in US, EU [homepage on the
exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol. Internet]. PharmaTimes online. 2017 [2017 Oct 05]. Available from: http://www.
2015;80(1):146–156. https://doi.org/10.1111/bcp.12590 pharmatimes.com/news/viivjanssens_two-drug_hiv_regimen_filed_in_us,_
32. Colbers A, Gingelmaier A, Van Der Ende M, Rijnders B, Burger D. Pharmacokinetics, eu_1194731
safety and transplacental passage of rilpivirine in pregnancy: Two cases. AIDS. 51. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular
2014;28(2):288–290. https://doi.org/10.1097/QAD.0000000000000100 cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week
33. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet.
the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818. https:// 2017;390(10101):1499–1510. https://doi.org/10.1016/S0140-6736(17)31917-7
doi.org/10.1056/NEJMoa1215541 52. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV
34. Aboud M, Kaplan R, Lombaard J, et al. Superior efficacy of dolutegravir (DTG) plus preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983.
2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ https://doi.org/10.1097/QAD.0000000000001145
ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the 53. Van’t Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of
DAWNING study. IAS 2017; 23–26 July 2017; Paris, France; 2017. rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral
35. Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line formulation. Antimicrob Agents Chemother. 2010;54(5):2042–2050. https://doi.
antiretroviral therapy for the treatment of HIV infection: A systematic review and org/10.1128/AAC.01529-09
network meta-analysis. Lancet HIV. 2016;3(11):e510–e520. https://doi. 54. Verloes R, Deleu S, Niemeijer N, Crauwels H, Meyvisch P, Williams P. Safety,
org/10.1016/S2352-3018(16)30091-1 tolerability and pharmacokinetics of rilpivirine following administration of a long-
36. De Boer MG, Van Den Berk GE, Van Holten N, et al. Intolerance of dolutegravir- acting formulation in healthy volunteers. HIV Med. 2015;16(8):477–484. https://
containing combination antiretroviral therapy regimens in real-life clinical practice. doi.org/10.1111/hiv.12247
AIDS. 2016;30(18):2831–2834. https://doi.org/10.1097/QAD.0000000000001279 55. Jackson AG, Else LJ, Mesquita PM, et al. A compartmental pharmacokinetic
37. Borghetti A, Baldin G, Capetti A, et al. Efficacy and tolerability of dolutegravir and evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure
two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically prophylaxis. Clin Pharmacol Ther. 2014;96(3):314–323. https://doi.org/10.1038/
suppressed patients. AIDS. 2017;31(3):457–459. https://doi.org/10.1097/ clpt.2014.118
QAD.0000000000001357 56. Glaubius RL, Parikh UM, Hood G, et al. Deciphering the effects of injectable pre-
38. Kheloufi F, Boucherie Q, Blin O, Micallef J. Neuropsychiatric events and exposure prophylaxis for combination human immunodeficiency virus
dolutegravir in HIV patients: A worldwide issue involving a class effect. AIDS. prevention. Open Forum Infect Dis. 2016;3(3):ofw125. https://doi.org/10.1093/
2017;31(12):1775–1777. https://doi.org/10.1097/QAD.0000000000001557 ofid/ofw125
39. Cailhol J, Rouyer C, Alloui C, Jeantils V. Dolutegravir and neuropsychiatric adverse 57. McGowan I, Dezzutti CS, Siegel A, et al. An open-label multiple dose phase 1
events: A continuing debate. AIDS. 2017;31(14):2023–2024. https://doi. assessment of long-acting rilpivirine. 9th IAS Conference on HIV Science; 23–26
org/10.1097/QAD.0000000000001596 July 2017; Paris, France; 2017.
40. Kheloufi F, Allemand J, Mokhtari S, Default A. Psychiatric disorders after starting 58. Bekker L-G, Li SS, Tolley E, et al. HPTN 076: TMC278 LA safe, tolerable and
dolutegravir: Report of four cases. AIDS. 2015;29(13):1723–1725. https://doi. acceptable for HIV pre-exposure prophylaxis. Conference on Retroviruses and
org/10.1097/QAD.0000000000000789 Opportunistic Infections; 14 Feb 2017; Seattle, Washington; 2017.
41. Eiden C, Peyriere H, Peytavin G, Reynes J. Severe insomnia related to high 59. Sista ND, Li S, Marzinke M, et al. HPTN 076: Safety and pharmacokinetics of
concentrations of raltegravir. AIDS. 2011;25(5):725–727. https://doi.org/10.1097/ rilpivirine LA through week 76 in HIV-uninfected women. 9th IAS Conference on
QAD.0b013e32834465c8 HIV Science; 23–26 July 2017; Paris, France; 2017.
42. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with 60. Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: A
starting raltegravir: A report of four cases. AIDS. 2008;22(14):1890–1892. https:// systematic review and meta-analysis. AIDS. 2014;28(18):2721–2727. https://doi.
doi.org/10.1097/QAD.0b013e32830e0169 org/10.1097/QAD.0000000000000505
43. Lafay-Chebassier C, Chavant F, Favreliere S, Pizzoglio V, Perault-Pochat MC. Drug- 61. Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure
induced depression: A case/non case study in the French pharmacovigilance database. prophylaxis for adults and adolescents: A systematic review. Clin Infect Dis.
Therapie. 2015;70(5):425–432. https://doi.org/10.2515/therapie/2015026 2015;60(Suppl 3):S170–S176. https://doi.org/10.1093/cid/civ092
44. Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks 62. Foster R, McAllister J, Read TR, et al. Single-tablet emtricitabine-eilpivirine-
of clinical obesity? J Virus Eradic. 2019;5(1):41–43. tenofovir as HIV postexposure prophylaxis in men who have sex with men. Clin
45. Zash R, Jacobson D, Mayondi G, et al. Dolutegravir/tenofovir/emtricitabine (DTG/ Infect Dis. 2015;61(8):1336–1341. https://doi.org/10.1093/cid/civ511
TDF/FTC) started in pregnancy is as safe as efavirenz/tenofovir/emtricitabine 63. Allavena C, Bonnet B, Merrien D, et al. Compliance to and safety of tenofovirDF/
(EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana. IAS 2017; emtricitabine/rilpivirine in post-exposure prophylaxis. 9th IAS Conference on HIV
23–26 July 2017; Paris, France; 2017. Science; 23–26 July 2017; Paris, France; 2017.

http://www.sajhivmed.org.za 65 Open Access